Drug Trial Radar · NCT05938270
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Sep 21, 2023
Primary completion
Jun 15, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
Conditions
- Prostate Cancer
Interventions
Saruparib (AZD5305)Drug
Saruparib (AZD5305) given orally once daily
DarolutamideDrug
Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
No TreatmentOther
No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fold change in % γH2AX positive cells from baseline value in tumour samplesTime frame: Tumour biopsy taken at diagnosis within approx 2 months of Day 1 planned start of study treatment; post treatment tumour biopsy taken following 21 days (+ up to 7 days) of study treatment
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Detroit, Michigan
Research Site
Providence, Rhode Island
Research Site
Melbourne, Australia
Research Site
South Brisbane, Australia
Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Amsterdam, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Valencia, Spain
Research Site
Cambridge, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.